<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
	<headerData>
        <submissionType>144</submissionType>
                <filerInfo>
            <filer>
                <filerCredentials>
                    <cik>0002050167</cik>
                    <ccc>XXXXXXXX</ccc>
                </filerCredentials>
            </filer>
        <liveTestFlag>LIVE</liveTestFlag>




                </filerInfo>
    </headerData>

     <formData>
        <issuerInfo>
            <issuerCik>0001842295</issuerCik>
			<issuerName>MAZE THERAPEUTICS, INC.</issuerName>


			    <secFileNumber>001-42490</secFileNumber>


			<issuerAddress>
				<com:street1>171 OYSTER POINT BOULEVARD, SUITE 300</com:street1>
                				<com:city>SOUTH SAN FRANCISCO</com:city>
				<com:stateOrCountry>CA</com:stateOrCountry>
				<com:zipCode>94080</com:zipCode>
			</issuerAddress>

			<issuerContactPhone>650-850-5070</issuerContactPhone>
			<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Atul Dandekar</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>

			<relationshipsToIssuer>

				    <relationshipToIssuer>Officer</relationshipToIssuer>

			</relationshipsToIssuer>
		</issuerInfo>

				          <securitiesInformation>
			<securitiesClassTitle>Common Stock</securitiesClassTitle>
			<brokerOrMarketmakerDetails>
				<name>Morgan Stanley Smith Barney LLC</name>
				<address>
				<com:street1>Executive Financial Services</com:street1>
                				<com:street2>1 New York Plaza, 8th Floor</com:street2>
                				<com:city>New York</com:city>
				<com:stateOrCountry>NY</com:stateOrCountry>
				<com:zipCode>10004</com:zipCode>
				</address>
			</brokerOrMarketmakerDetails>
			<noOfUnitsSold>6679</noOfUnitsSold>
			<aggregateMarketValue>177200</aggregateMarketValue>
			<noOfUnitsOutstanding>55549168</noOfUnitsOutstanding>
			<approxSaleDate>09/02/2026</approxSaleDate>
			<securitiesExchangeName>NASDAQ</securitiesExchangeName>
		</securitiesInformation>

    		       <securitiesToBeSold>
         <securitiesClassTitle>Common Stock</securitiesClassTitle>
         <acquiredDate>09/01/2026</acquiredDate>
         <natureOfAcquisitionTransaction>Restricted Stock Unit Vesting</natureOfAcquisitionTransaction>
                  <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
                  <isGiftTransaction>N</isGiftTransaction>
		          <amountOfSecuritiesAcquired>6679</amountOfSecuritiesAcquired>
                  <paymentDate>09/01/2026</paymentDate>
                  <natureOfPayment>Compensation</natureOfPayment>
      </securitiesToBeSold>

    <nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>


     <securitiesSoldInPast3Months>
         <sellerDetails>
            <name>Atul Dandekar</name>
            <address>
               <com:street1>c/o Maze Therapeutics, Inc.</com:street1>
                              <com:street2>171 Oyster Point Boulevard, Suite 300</com:street2>
                              <com:city>South San Francisco</com:city>
               <com:stateOrCountry>CA</com:stateOrCountry>
               <com:zipCode>94080</com:zipCode>
            </address>
         </sellerDetails>
         <securitiesClassTitle>Common Stock</securitiesClassTitle>
         <saleDate>06/29/2026</saleDate>
         <amountOfSecuritiesSold>7500</amountOfSecuritiesSold>
         <grossProceeds>210150.00</grossProceeds>
      </securitiesSoldInPast3Months>

     <securitiesSoldInPast3Months>
         <sellerDetails>
            <name>Atul Dandekar</name>
            <address>
               <com:street1>c/o Maze Therapeutics, Inc.</com:street1>
                              <com:street2>171 Oyster Point Boulevard, Suite 300</com:street2>
                              <com:city>South San Francisco</com:city>
               <com:stateOrCountry>CA</com:stateOrCountry>
               <com:zipCode>94080</com:zipCode>
            </address>
         </sellerDetails>
         <securitiesClassTitle>Common Stock</securitiesClassTitle>
         <saleDate>07/29/2026</saleDate>
         <amountOfSecuritiesSold>7500</amountOfSecuritiesSold>
         <grossProceeds>205031.44</grossProceeds>
      </securitiesSoldInPast3Months>

     <securitiesSoldInPast3Months>
         <sellerDetails>
            <name>Atul Dandekar</name>
            <address>
               <com:street1>c/o Maze Therapeutics, Inc.</com:street1>
                              <com:street2>171 Oyster Point Boulevard, Suite 300</com:street2>
                              <com:city>South San Francisco</com:city>
               <com:stateOrCountry>CA</com:stateOrCountry>
               <com:zipCode>94080</com:zipCode>
            </address>
         </sellerDetails>
         <securitiesClassTitle>Common Stock</securitiesClassTitle>
         <saleDate>08/28/2026</saleDate>
         <amountOfSecuritiesSold>7500</amountOfSecuritiesSold>
         <grossProceeds>206823.75</grossProceeds>
      </securitiesSoldInPast3Months>

    		<remarks>The reported sale was mandated by the Issuer and includes an amount necessary to satisfy tax withholding obligations resulting from the vesting and settlement of restricted stock units granted pursuant to an equity incentive award.</remarks>

        <noticeSignature>
            <noticeDate>09/02/2026</noticeDate>
                        <signature> /s/ Atul Dandekar</signature>
        </noticeSignature>
	</formData>
    </edgarSubmission>
